Advertisement

Internal and Emergency Medicine

, Volume 7, Issue 2, pp 181–182 | Cite as

Colchicine is safe and effective for secondary prevention of recurrent pericarditis

  • Francesca Gianni
  • Monica SolbiatiEmail author
  • Gruppo di Autoformazione Metodologica (GrAM)
CE - THE CUTTING EDGE: RESEARCH UPDATE

Background

Recurrence is the most common complication of acute pericarditis, occurring in 10–30 % of patients with a first episode, and again in up to 50 % after a first recurrence of acute pericarditis [1].

Observational studies [2, 3, 4] and an open-label, single-center, randomized trial [5] show that colchicine can significantly reduce pericarditis recurrence rate. On the basis of these data, colchicine is recommended in the European Society of Cardiology guidelines (level of evidence B, class IIa indication) for the initial attack as well as the prevention of recurrences of acute pericarditis [6].

However, no multicenter, double-blind, randomized trial has confirmed these favorable findings.

Summary

The CORP (COlchicine for Recurrent Pericarditis) trial [7] is a prospective, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of colchicine (1.0–2.0 mg on the first day, followed by a maintenance dose of 0.5–1.0 mg/day for 6 months) in...

Keywords

Colchicine Pericarditis Relative Risk Reduction Cardiac Tamponade Absolute Risk Reduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

None.

References

  1. 1.
    Adler Y, Finkelstein Y, Guindo J et al (1998) Colchicine treatment for recurrent pericarditis: a decade of experience. Circulation 97:2183–2185PubMedGoogle Scholar
  2. 2.
    Guindo J, Rodriguez de la Serna A et al (1990) Recurrentpericarditis. Relief with colchicine. Circulation 82:1117–1120PubMedCrossRefGoogle Scholar
  3. 3.
    Adler Y, Zandman-Goddard G, Ravid M et al (1994) Usefulness of colchicine in preventing recurrences of pericarditis. Am J Cardiol 73:916–917PubMedCrossRefGoogle Scholar
  4. 4.
    Millaire A, de Groote P, Decoulx E et al (1994) Treatment of recurrent pericarditis with colchicine. Eur Heart J 15:120–124PubMedGoogle Scholar
  5. 5.
    Imazio M, Bobbio M, Cecchi E et al (2005) Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation 112:2012–2016PubMedCrossRefGoogle Scholar
  6. 6.
    Maisch B, Seferovic PM, Ristic AD et al (2004) Guidelines on the diagnosis and management of pericardial diseases executive summary. Eur Heart J 6(10):1046–1047Google Scholar
  7. 7.
    Imazio M, Brucato A, Cemin R et al (2011) Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med 155:409–414PubMedGoogle Scholar
  8. 8.
    Imazio M, Cecchi E, Ierna S, Trinchero R, ICAP Investigators (2007) Investigation on colchicine for acute pericarditis: a multicenter randomized placebo-controlled trial evaluating the clinical benefits of colchicine as adjunct to conventional therapy in the treatment and prevention of pericarditis; study design and rationale. J Cardiovasc Med (Hagerstown) 8:613–617CrossRefGoogle Scholar

Copyright information

© SIMI 2012

Authors and Affiliations

  • Francesca Gianni
    • 1
  • Monica Solbiati
    • 1
    Email author
  • Gruppo di Autoformazione Metodologica (GrAM)
  1. 1.Medicina Interna II, Azienda Ospedaliera L. Sacco, Università degli Studi di MilanoMilanItaly

Personalised recommendations